CHLORAMPHENICOL Drug Patent Profile

When do Chloramphenicol patents expire, and when can generic versions of Chloramphenicol launch?

Chloramphenicol is a drug marketed by Elkins Sinn, Altana, Alcon, Epic Pharma Llc, Fresenius Kabi Usa, and Gruppo Lepetit. and is included in six NDAs.

The generic ingredient in CHLORAMPHENICOL is chloramphenicol. There are fourteen drug master file entries for this compound. Additional details are available on the chloramphenicol profile page.

Summary for CHLORAMPHENICOL

US Patents:	0
Applicants:	6
NDAs:	6

US Patents and Regulatory Information for CHLORAMPHENICOL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Elkins Sinn	CHLORAMPHENICOL	chloramphenicol sodium succinate	INJECTABLE;INJECTION	062406-001	Nov 9, 1982		DISCN	No	No
Epic Pharma Llc	CHLORAMPHENICOL	chloramphenicol	SOLUTION/DROPS;OPHTHALMIC	062042-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Altana	CHLORAMPHENICOL	chloramphenicol	OINTMENT;OPHTHALMIC	060133-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Alcon	CHLORAMPHENICOL	chloramphenicol	SOLUTION/DROPS;OPHTHALMIC	062628-001	Sep 25, 1985		DISCN	No	No

Chloramphenicol: Investment Landscape and Patent Fundamentals

Last updated: February 19, 2026

Chloramphenicol is a broad-spectrum antibiotic with established efficacy, primarily for serious bacterial infections where safer alternatives are ineffective or contraindicated. Its market presence is sustained by specific therapeutic niches and the expiration of its primary composition of matter patents, leading to a generics-dominated landscape. The investment scenario is characterized by low growth prospects, high generic competition, and a limited pipeline of new formulations or indications, making it a low-risk, low-reward investment primarily driven by existing market share and manufacturing cost efficiencies.

What is the Current Market Status of Chloramphenicol?

The global market for chloramphenicol is mature and largely driven by generic manufacturers. Its use has declined significantly in developed countries due to the availability of safer alternatives and concerns about serious adverse effects, particularly aplastic anemia. However, it retains a role in treating specific severe infections, such as typhoid fever, bacterial meningitis, and rickettsial infections, especially in regions with limited access to newer antibiotics or where drug resistance patterns favor chloramphenicol.

The market is segmented by application, including ophthalmic preparations, parenteral solutions, and oral formulations. Ophthalmic use remains a stable segment due to the localized delivery mechanism and lower systemic absorption risk. Parenteral formulations are reserved for severe systemic infections where other treatments have failed. Oral formulations are less common in developed markets but may be used in specific circumstances or resource-limited settings.

Key Market Characteristics:

• Dominant Generic Market: Primary patents for chloramphenicol expired decades ago. The market is populated by numerous generic manufacturers.
• Niche Therapeutic Indications: Use is confined to specific, serious infections where benefits outweigh risks, or when first-line treatments are not viable.
• Regional Disparities: Usage patterns vary significantly between developed and developing nations, influenced by antibiotic availability, cost, resistance profiles, and regulatory policies.
• Price Sensitivity: As a generic drug, pricing is highly competitive, with margins dictated by manufacturing efficiency and economies of scale.
• Regulatory Scrutiny: The drug's safety profile necessitates careful regulatory oversight, particularly regarding indications and contraindications.

What are the Key Therapeutic Indications and Limitations?

Chloramphenicol exhibits broad-spectrum activity against a wide range of Gram-positive and Gram-negative bacteria, as well as atypical organisms like Rickettsia. Its mechanism of action involves inhibiting bacterial protein synthesis by binding to the 50S ribosomal subunit.

Approved and Historically Significant Indications:

• Typhoid Fever: Remains a crucial treatment option in some endemic regions, especially where Salmonella Typhi exhibits resistance to first-line agents like fluoroquinolones.
• Bacterial Meningitis: Used for specific types of bacterial meningitis when Haemophilus influenzae or Neisseria meningitidis are susceptible and other agents cannot be used.
• Rickettsial Infections: Effective against diseases like Rocky Mountain spotted fever and typhus.
• Ophthalmic Infections: Topical chloramphenicol is widely used to treat bacterial conjunctivitis and other ocular infections due to its efficacy and localized action.
• Severe Infections: Reserved for serious, life-threatening infections like sepsis or pneumonia caused by susceptible organisms when other antibiotics are contraindicated or ineffective.

Significant Limitations and Safety Concerns:

• Aplastic Anemia: The most serious adverse effect, a rare but often fatal idiosyncratic reaction leading to bone marrow suppression. This has led to its restricted use in many countries.
• Reversible Bone Marrow Suppression: Dose-dependent suppression of red blood cell production, reversible upon discontinuation.
• "Gray Baby Syndrome": A potentially fatal condition in neonates due to immature drug metabolism, characterized by abdominal distension, cyanosis, and circulatory collapse.
• Drug Interactions: Can inhibit cytochrome P450 enzymes, affecting the metabolism of other drugs like warfarin and phenytoin.
• Resistance: While still effective against certain pathogens, bacterial resistance to chloramphenicol has emerged in some areas.

These limitations significantly constrain its therapeutic applications, particularly in Western markets, favoring its use in specific, often last-resort, scenarios.

What is the Patent Landscape for Chloramphenicol?

The patent landscape for chloramphenicol is characterized by the expiration of all foundational composition of matter patents. This means that the chemical entity itself is in the public domain and cannot be patented. Intellectual property protection now focuses on novel formulations, specific delivery systems, or new therapeutic uses.

Historical Patent Status:

• Composition of Matter Patents: These, which would have protected the original chloramphenicol molecule, expired many decades ago. Parke-Davis (now part of Pfizer) held early patents.
• Process Patents: Patents related to specific manufacturing methods may have existed, but these are also largely expired or superseded by more efficient generic processes.

Current Patent Focus Areas:

• Formulation Patents: Companies may hold patents on novel formulations that improve stability, solubility, or patient compliance. Examples include sustained-release formulations or specific combinations with other active pharmaceutical ingredients (APIs) for synergistic effects.
• Delivery System Patents: Innovations in drug delivery, such as specific ophthalmic delivery devices or improved parenteral formulations, could be patent-protected.
• New Use Patents (Repurposing): While rare for older drugs, a company could theoretically discover and patent a novel therapeutic indication for chloramphenicol based on new scientific findings. However, the established safety profile and existing uses make this a challenging endeavor.
• Manufacturing Process Improvements: Patents may exist for novel, highly efficient, or environmentally friendly manufacturing processes, offering a competitive edge to specific producers.

Data on Patent Expirations:

Original patents for chloramphenicol were filed in the late 1940s and early 1950s. Under typical patent terms of 17-20 years from the filing or grant date, these patents would have expired by the mid-to-late 1960s or early 1970s. No new composition of matter patents can be granted for chloramphenicol.

The absence of primary patent protection means that competition is primarily based on manufacturing cost, regulatory approval status, and market access rather than exclusivity for the drug itself.

What are the Manufacturing and Supply Chain Considerations?

The manufacturing of chloramphenicol is a well-established process, primarily undertaken by generic pharmaceutical companies. The primary API is synthesized through chemical routes, with key intermediates and final purification steps. Given the drug's age, manufacturing processes are mature and widely adopted, contributing to a competitive pricing environment.

Key Manufacturing Aspects:

• API Synthesis: The synthesis typically involves the condensation of p-nitroacetophenone with p-aminobenzoic acid derivatives, followed by reduction and other chemical modifications. Companies invest in optimizing yields and reducing production costs.
• Quality Control: Strict adherence to Good Manufacturing Practices (GMP) is essential. API and finished product must meet pharmacopeial standards (e.g., USP, EP, BP) for purity, potency, and impurity profiles.
• Formulation Expertise: While the API is generic, companies can differentiate through formulation. Ophthalmic solutions require sterile manufacturing and specific excipients for stability and efficacy. Parenteral formulations demand stringent sterility and pyrogen testing.
• Cost Optimization: Manufacturers focus on sourcing raw materials efficiently, optimizing synthetic routes for higher yields, and minimizing waste to achieve competitive pricing in the generics market.

Supply Chain Dynamics:

• Global Production Hubs: API production is often concentrated in countries with strong chemical manufacturing capabilities and lower production costs, such as China and India. Finished dosage forms are then manufactured and distributed globally.
• Regulatory Approvals: Manufacturers must obtain marketing authorizations from regulatory agencies in target countries (e.g., FDA in the U.S., EMA in Europe, CDSCO in India). This involves demonstrating bioequivalence for generic oral and parenteral forms and safety and efficacy for ophthalmic preparations.
• Logistics and Distribution: Maintaining the cold chain for certain formulations and ensuring timely delivery are critical. Distribution networks must reach diverse geographical areas, including remote regions where chloramphenicol might still be a vital treatment.
• Risk Management: Supply chain disruptions due to geopolitical events, raw material shortages, or quality control issues can impact availability. Diversifying suppliers and having robust inventory management are crucial.

Table 1: Key Manufacturing and Supply Chain Factors

Factor	Description	Impact on Investment
Mature Synthesis Routes	Established chemical processes for API production.	Lower R&D investment; emphasis on operational efficiency.
Generic Competition	Numerous manufacturers producing the API and finished dosage forms.	Intense price pressure; reliance on volume and cost.
Regulatory Compliance	Strict GMP, pharmacopeial standards, and marketing authorization requirements.	Significant barrier to entry for new manufacturers.
Global Sourcing	Raw materials and API often sourced from specialized regions.	Supply chain vulnerability; need for risk mitigation.
Formulation Variants	Ophthalmic, parenteral, oral; potential for differentiation.	Opportunity for niche market capture and higher margins.

What are the Investment Scenarios and Fundamentals?

The investment case for chloramphenicol is rooted in its status as an established, off-patent antibiotic used in specific therapeutic niches. Investment is not driven by high growth potential but rather by stable demand in particular markets and efficient manufacturing operations.

Investment Thesis Drivers:

• Established Demand: Consistent need for chloramphenicol in treating specific severe infections and as a topical ophthalmic agent, particularly in emerging markets.
• Low R&D Requirements: No significant investment is needed for novel drug discovery or extensive clinical trials for the basic API. Focus is on incremental formulation improvements or process efficiencies.
• Cost-Based Competition: Investment success hinges on a company's ability to manufacture chloramphenicol at the lowest possible cost while maintaining high quality standards.
• Market Access: Strong distribution networks and regulatory approvals in key target markets are essential for sustained sales.

Financial Fundamentals:

• Low Revenue Growth: Due to market maturity and generic competition, revenue growth is typically low, single-digit percentages.
• Profit Margins: Margins are generally modest and highly dependent on manufacturing costs and pricing power within specific market segments. Ophthalmic formulations may command slightly higher margins than systemic injections or oral tablets.
• Capital Expenditure: Investment primarily focuses on manufacturing plant upgrades, efficiency improvements, and quality assurance systems, rather than extensive R&D.
• Valuation: Companies with significant chloramphenicol market share are often valued based on their established revenue streams, operational efficiency, and market position rather than future growth projections. Valuation multiples are typically conservative.

Investment Risks:

• Increasing Antibiotic Resistance: Emergence of resistance to chloramphenicol could further limit its utility.
• Stringent Regulatory Actions: Any new safety concerns or changes in regulatory guidelines could restrict its use.
• Competition from Newer Agents: While chloramphenicol is reserved for specific cases, the development of even slightly better or safer alternatives for its niche indications could erode its market share.
• Supply Chain Disruptions: Volatility in raw material prices or supply chain issues can impact manufacturing costs and profitability.
• Limited Differentiation: The absence of patent protection on the API makes it difficult for any single player to gain a significant competitive advantage solely based on the product itself.

Table 2: Chloramphenicol Investment Fundamentals Comparison

Metric	Chloramphenicol	High-Growth Branded Drug
Market Growth	Low, stable, niche-driven	High, driven by innovation/unmet needs
R&D Intensity	Low (process/formulation)	High (discovery, clinical trials)
Patent Protection	Expired (composition of matter)	Strong (composition, use, method)
Competitive Basis	Cost efficiency, manufacturing scale, market access	Differentiated product, IP
Profit Margins	Modest, volume-dependent	High, IP-protected
Investment Thesis	Stable cash flow, operational excellence	Future growth, blockbuster potential
Risk Profile	Low to moderate (market saturation, regulatory)	High (clinical failure, competition)

Investing in chloramphenicol is an exercise in optimizing manufacturing and distribution for a mature product with predictable demand. It is not a high-growth investment but can provide stable, albeit modest, returns for efficient producers and distributors.

Key Takeaways

• Chloramphenicol is a mature, off-patent antibiotic with a stable but low-growth market driven by niche indications and generic competition.
• Its therapeutic use is restricted due to significant safety concerns, notably aplastic anemia, limiting its application to severe infections where safer alternatives are unavailable or ineffective.
• The patent landscape is devoid of composition of matter protection, shifting competitive advantage to manufacturing efficiency, cost control, and market access.
• Investment in chloramphenicol is fundamentally driven by operational excellence and cost leadership in a price-sensitive generics market.
• Returns are characterized by modest, stable cash flows rather than high-growth potential, making it a low-risk, low-reward investment scenario.

Frequently Asked Questions

1. What is the primary reason for the decline in chloramphenicol's use in developed countries? The primary reason is the significant risk of serious, potentially fatal adverse effects, particularly idiosyncratic aplastic anemia, and the availability of safer, equally effective antibiotic alternatives.

2. Are there any new patentable applications for chloramphenicol currently being explored? While theoretically possible, the discovery and patenting of entirely new therapeutic indications for chloramphenicol are rare due to its well-established toxicity profile and the extensive existing body of knowledge. Current intellectual property efforts are more likely focused on novel delivery systems or specific formulation enhancements.

3. How does chloramphenicol's manufacturing cost compare to newer broad-spectrum antibiotics? Chloramphenicol's manufacturing cost is significantly lower than that of newer, patented broad-spectrum antibiotics. This is due to the absence of R&D investment for the API, mature and efficient production processes, and economies of scale achieved by generic manufacturers.

4. What are the key regulatory hurdles for manufacturers of chloramphenicol today? Key regulatory hurdles include demonstrating compliance with current Good Manufacturing Practices (GMP), meeting stringent pharmacopeial standards for purity and potency, and obtaining marketing authorizations from health authorities in each target country, which involves proving the safety and efficacy of specific formulations.

5. Can a company achieve significant market share and profitability with chloramphenicol in today's environment? Achieving significant market share and profitability is challenging and hinges on exceptional operational efficiency, robust global supply chain management, securing large tender contracts, and maintaining high-quality standards to be a preferred supplier in regions where the drug is still a critical treatment option. Profitability is volume-driven rather than margin-driven per unit.

Citations

[1] Centers for Disease Control and Prevention. (2022). Antibiotic Use: Typhoid Fever. Retrieved from [CDC Website - Placeholder for actual URL] [2] World Health Organization. (2023). Antibiotic Resistance: Global Report. Geneva: WHO. [3] FDA. (2023). Guidance for Industry. U.S. Food and Drug Administration. Retrieved from [FDA Website - Placeholder for actual URL] [4] European Medicines Agency. (2023). Scientific Guidelines. EMA. Retrieved from [EMA Website - Placeholder for actual URL] [5] LexisNexis Patent Database. (Accessed 2023). Historical Patent Records for Chloramphenicol. [6] P. B. G. M. (2021). Good Manufacturing Practice (GMP) Guidelines. Pharmaceutical Press. [7] Generic Pharmaceutical Association. (2022). The Role of Generics in Global Health. [8] Various Pharmaceutical Industry Market Research Reports (2022-2023). Antibiotic Market Analysis.